March 2026 Research Update

This month, the treatment-related research ranged from a single-patient report in an adult to a new one-time gene-therapy style approach in mice. Together, these studies add early signals that boosting bone-building activity can be linked with pseudofracture healing in an individual, and that longer-lasting ways of restoring alkaline phosphatase activity are being tested in the lab. The common thread is durability: both reports focused on changes that held up over months rather than short-term shifts. [1] [2]

In one adult with pediatric-onset hypophosphatasia and pseudofractures in both thigh bones, teriparatide (a bone-building medicine) was followed by improved symptoms and imaging evidence that the fractures healed over 18 months. The report also described blood marker changes, including alkaline phosphatase and pyridoxal 5'-phosphate moving into the normal range during follow-up. Because this was one person without a comparison group, it shows what is possible in an individual case, not what will happen for most people. [1]

In a severe hypophosphatasia mouse model, researchers tested an approach that uses a lentiviral vector to help a person or animal's own blood-forming stem cells make a soluble form of TNALP (the enzyme that is low in hypophosphatasia). The study reported durable normalization of plasma alkaline phosphatase, improvement in skeletal problems, and prevention of early death in the mice. This is preclinical work, so it does not tell us how this would perform in people, but it clarifies what kinds of long-lasting enzyme restoration strategies are being pursued. [2]

For patients and caregivers, this month adds a clearer picture of how wide the treatment research spectrum is right now: from a single adult case that links a bone-building drug with pseudofracture healing, to a lab-based effort aiming for a one-time, durable enzyme replacement strategy. The teriparatide report may matter now mainly as a documented experience in one person, rather than proof of a general result. The stem-cell gene therapy work matters later if it is confirmed and translated safely to humans, because it targets a long-term fix for low alkaline phosphatase activity, but it is not a human treatment result at this stage. What remains uncertain is how often similar healing would be seen in other adults with HPP, and whether the mouse gene-therapy approach can be made safe and effective in people. [1] [2]

This month, two laboratory studies made the biology of hypophosphatasia feel less "bone-only" by pointing to changes in specialized cells in the brain and in tooth-forming cells. In mice lacking TNAP, immune cells in the brain (microglia) looked and behaved more like they were in an inflammatory state, alongside movement and strength differences. In patient-derived tooth-cell models, a nerve-related protein (NEFL) stood out as a possible driver of abnormal tooth-cell shape, partly separate from low alkaline phosphatase activity. [3] [4]

In an infantile hypophosphatasia mouse model, microglia had larger cell bodies and shorter branches, and the study reported higher levels of multiple inflammatory and "cell cleanup" markers. The mice also had slower early development and weaker performance on simple sensorimotor measures, such as grip strength and activity in an open area. The researchers also reduced TNAP in isolated microglia and saw inflammatory shifts, which supports the idea that some of these changes can come from microglia themselves and not only from the rest of the body. [3]

In a separate cell-model study using patient-derived iPSCs (cells reprogrammed to act like early stem cells), researchers made odontoblast-like cells, which resemble tooth-forming cells. Cells modeling odontohypophosphatasia showed higher NEFL and had problems forming normal cell extensions, while "rescued" cells had more normal mineralization-related features. Lowering NEFL partly improved extension growth without changing alkaline phosphatase activity, and raising NEFL made extensions worse in rescued cells, suggesting NEFL may contribute to tooth-cell abnormalities beyond enzyme activity alone. [4]

For patients, these lab studies mainly add understanding rather than changing anything now. The mouse work suggests that TNAP deficiency can coincide with brain immune cell inflammation-like changes and movement or strength differences, which may help researchers explore why some people report non-bone symptoms, but it does not prove the same process occurs in humans. The tooth-cell model suggests that dental features in some forms of HPP might involve specific cell-shape pathways (like NEFL) in addition to low alkaline phosphatase, which could matter later if it leads to new research targets. What remains uncertain is how directly these cell and mouse findings map to day-to-day symptoms in people, and whether changing these pathways would improve patient outcomes. [3] [4]